Page 50 - Haematologica May 2022

H.T. Greinix et al.
P<0.001), and a female donor for a male recipient (HR 1.2; 1.12-1.28; P<0.001) were all associated with increased risk for aGvHD grades III-IV whereas RIC (HR 0.88 (0.83- 0.94); P<0.001), male donor (HR 0.87 (0.81-0.94); P<0.001) or female donor for a female recipient (HR 0.89 (0.82-0.96); P=0.004) were associated with a lower inci- dence, respectively. Use of ATG/alemtuzumab reduced risk for aGvHD grades III-IV per decade (HR 0.73 (0.67- 0.8), P<0.001). Of note is that aGvHD grades III-IV also
decreased per decade in patients treated without ATG or alemtuzumab (HR 0.56 (0.53-0.6); P<0.001).
Outcomes
For the total study population (n=102,557), three-year OS significantly increased from 49% (48-51%), to 51% (50-52%), 52% (52-53%), 53% (53-54%), and 54% (53- 54%) for the periods 1990-1995, 1996-2000, 2001-2005, 2006-2010, and 2011-2015, respectively (Figure 2).
Figure 2. Three-year overall survival over time for the whole patient cohort. The probability of OS for all patients was calculated using the Kaplan Meier estimator. Data are shown according to transplantation periods 1990-1995, 1996-2000, 2001-2005, 2006-2010 and 2011-2015.
Figure 3. Three-year overall survival over time. (A) Three-year overall survival after aGvHD grades II-IV over time. The probability of OS for patients experiencing aGvHD grades II-IV was calculated using the Kaplan Meier estimator. Data are shown according to transplantation periods 1990-1995, 1996-2000, 2001-2005, 2006-2010 and 2011-2015. (B) Three-year overall survival after aGvHD grades III-IV over time. The probability of OS for patients experiencing aGvHD grades III-IV was calculated using the Kaplan Meier estimator. Data are shown according to transplantation periods 1990-1995, 1996-2000, 2001-2005, 2006-2010 and 2011-2015.
AB
1058
haematologica | 2022; 107(5)